Novel Turbidimetric Immunoassay Evaluated for Fecal Calprotectin
|
By LabMedica International staff writers Posted on 28 Sep 2016 |
|
Image: The BS-380 automatic biochemistry analyzer (Photo courtesy of Mindray).
Calprotectin is a multifunctional protein that plays an important role in the diagnosis and follow-up of inflammatory bowel disease and high levels of calprotectin in stool samples are associated with inflammation of the intestinal tract.
Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD, but the problem with most of the fecal calprotectin assays is the rather long test-turnaround times, before the results are available to the physician.
Scientists at Uppsala University (Sweden) optimized a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin and validated the assay for two clinical autoanalyzers using routine fecal samples. They compared the PETIA with a commercial enzyme-linked immunosorbent assay (ELISA), known as the Bühlmann fCAL ELISA (Bühlmann Laboratories, Schönenbuch, Switzerland). This new latex based turbidimetric calprotectin assay applies particles coated with anti-human calprotectin (MRP8/14) antibodies: the agglutination is proportional to the calprotectin concentration.
The fecal calprotectin PETIA was validated on two chemistry analyzers, the Mindray BS-380 (Mindray, Shenzhen, China) and the Cobas 501 (Roche Diagnostics, Basel, Switzerland). The assay is linear in the range 11 μg/g to 2,000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10,000 μg/g to 15,000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3% to 8% in the 50 μg/g to100 μg/g range.
The authors concluded that the fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are concordant with the Bühlmann fecal MRP8/14 ELISA. The study was published in the September 2016 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Uppsala University
Bühlmann Laboratories
Mindray
Roche Diagnostics
Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD, but the problem with most of the fecal calprotectin assays is the rather long test-turnaround times, before the results are available to the physician.
Scientists at Uppsala University (Sweden) optimized a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin and validated the assay for two clinical autoanalyzers using routine fecal samples. They compared the PETIA with a commercial enzyme-linked immunosorbent assay (ELISA), known as the Bühlmann fCAL ELISA (Bühlmann Laboratories, Schönenbuch, Switzerland). This new latex based turbidimetric calprotectin assay applies particles coated with anti-human calprotectin (MRP8/14) antibodies: the agglutination is proportional to the calprotectin concentration.
The fecal calprotectin PETIA was validated on two chemistry analyzers, the Mindray BS-380 (Mindray, Shenzhen, China) and the Cobas 501 (Roche Diagnostics, Basel, Switzerland). The assay is linear in the range 11 μg/g to 2,000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10,000 μg/g to 15,000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3% to 8% in the 50 μg/g to100 μg/g range.
The authors concluded that the fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are concordant with the Bühlmann fecal MRP8/14 ELISA. The study was published in the September 2016 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Uppsala University
Bühlmann Laboratories
Mindray
Roche Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Urine Analyzer
respons® UDS100
HPV Test
Allplex HPV28 Detection
Latest Clinical Chem. News
- Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
- New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
- Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
- Machine Learning Model Uses Routine Lab Tests to Support Heart Failure Classification
- NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
- Multiprotein Plasma Panel Identifies Remission in Vasculitis
- Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
- Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
- FDA Clears Roche Blood Test for Alzheimer’s Amyloid Pathology Assessment
- Blood Test Markers Could Help Identify Older Adults at Risk of Disability
- Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
- Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
- Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease
- Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease
- Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
- Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma
Channels
Clinical Chemistry
view channel
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more
New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
Stroke affects more than 795,000 Americans each year, leaving many survivors with lasting motor, speech, and cognitive deficits. Because rehabilitation outcomes vary widely, clinicians still face challenges... Read more
NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies... Read more
Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
Lung cancer is often diagnosed at advanced stages because symptoms typically appear late, while participation in low-dose computed tomography (LDCT) screening remains low. Imaging can also produce false-positive... Read moreMolecular Diagnostics
view channel
Urine Genomic Test Detects More Than Nine in Ten Suspected Bladder Cancers
Urgent evaluation for suspected bladder cancer often sends patients to cystoscopy, an invasive and resource-intensive procedure, even though relatively few ultimately have cancer. This places pressure... Read more
Liquid Biopsy Test Predicts Tissue of Origin in Cancer of Unknown Primary
Cancers of unknown primary and other uncertain tumor presentations can complicate therapy selection, especially in community oncology settings where subspecialty pathology resources may be limited.... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Microbiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Pathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Industry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more
